INTEGRATED ASSESSMENT OF SAFETY OF TWO MODES OF ERADICATION THERAPY OF HELICOBACTER PYLORI INFECTION IN PATIENTS WITH CHRONIC HEPATITIS C


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the results of a prospective randomized clinical study in parallel groups in which evaluated the safety of two modes of eradication therapy (ET) of Helicobacter pylori infection in patients with chronic hepatitis C (CHC) [OR - 1.40, 95% CI - 0,56-3,44]. The incidence of adverse events during the ET was higher in patients with concomitant HCV. In this group, patients had more frequent cumulative incidence of adverse events (n=28 vs n=18), regardless of the ET scheme appointed. ET have significant negative impact on the dynamics of biochemical markers of cytolytic and cholestatic syndromes, mostly in patients with concomitant HCV. Presence of hepatotoxic effect of drugs used for ET in some patients had no effect on the duration of treatment, but in order to avoid a significant drug-induced liver damage it is recommended to monitor the biochemical parameters during ET.

全文:

受限制的访问

作者简介

D. Andreev

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Email: dna-mit8@mail.ru
Teaching Assistant of the Department of Propedeutics of Internal Diseases and Gastroenterology Moscow

I. Maev

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Moscow

D. Dicheva

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Moscow

Y. Kucheryavy

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Moscow

参考

  1. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014;3:94-9.
  2. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.
  3. Malfertheiner P., Megraud F., O'Morain C., et al. Management of Helicobacter pylori infection -Maastricht IV / Florence Consensus Report. Gut. 2012;61:646-64.
  4. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М., 2015.
  5. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М., 2016.
  6. Morgan D.R, Crowe S.E. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J. Brandt. 10th ed. 2015.
  7. Li B.Z., Threapleton D.E., Wang J.Y., Xu J.M., Yuan J.Q., Zhang C., Li P., Ye Q.L., Guo B., Mao C., Ye D.Q. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.
  8. Andrade R.J., Camargo R., Lucena M.I., et al. Causality assessment in drug-induced hepatotoxicity. Expert Opin. Drug Saf. 2004; 3:329-44.
  9. Zapater P., Moreu R., Horga J.F. The diagnosis of drug-induced liver disease. Curr. Clin. Pharmacol. 2006;1:207-17.
  10. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. J. Antimicrob. Chemother. 2011;66(7):1431-46.
  11. Бурбелло А.Т., Бабак С.В., Андреев Б.В., Колбин А.С., Горячкина К.А. Неблагоприятные побочные реакции лекарственных средств (пособие для врачей) / Под ред. А.Т. Бурбелло. СПб., 2008.
  12. Alomar M.J. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83-94.
  13. Каримов М.М., Каримова Д.М., Вахабова Л.М., Саатов З.З. Последовательная терапия больных с язвенной болезнью двенадцатиперстной кишки. Доктор.Ру. 2015;2-2:12.
  14. Zhou Y.Q., Xu L., Wang B.F., et al. Modified sequential therapy regimen versus conventional triple therapy for Helicobacter pylori eradication in duodenal ulcer patients in China: a multicenter clinical comparative study. Gastroenterol. Res. Pract. 2012; 2012:405-25.
  15. Polson J.E. Hepatotoxicity due to antibiotics. Clin. Liver Dis. 2007;11(3):549-61.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##